title: Tacrolimus ointment in the treatment of eyelid dermatitis.
abstract: The safety and efficacy of tacrolimus ointment 0.1% (Protopic) in the treatment of atopic dermatitis of the eyelids were assessed in an open-label clinical trial of 21 patients with moderate to severe eyelid dermatitis. Of those 21 patients, 20 received study drug and were followed. Patients applied tacrolimus ointment 0.1% twice daily for 8 weeks and were followed for 2 additional weeks after the last day of treatment. Complete eye examinations were conducted throughout the study. Efficacy was assessed through the investigator's evaluation of the patients' individual signs and symptoms of eyelid dermatitis and the physician global assessment (PGA) of eyelid clinical response. Improvement in the investigator's evaluation of the signs and symptoms of eyelid dermatitis was observed during the study. A total of 80% of patients (16/20) experienced marked improvement or better in PGA at 8 weeks. Adverse events were limited to local burning and itching after the first few applications of study medication. Of the 20 patients, 12 reported burning (60%), and 5 reported itching (25%). There was no statistically significant increase in intraocular pressure (IOP) during the study compared with baseline. In addition, none of the patients developed cataracts or glaucoma during the study. In summary, tacrolimus ointment 0.1% may be a safe and effective treatment option for patients with moderate to severe eyelid dermatitis.
authors.affiliation: Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA. amykfreeman@hotmail.com
authors.forename: Amy Krupnick
authors.initials: AK
authors.lastname: Freeman
authors.forename: Janet
authors.initials: J
authors.lastname: Serle
authors.forename: Paul
authors.initials: P
authors.lastname: VanVeldhuisen
authors.forename: Leah
authors.initials: L
authors.lastname: Lind
authors.forename: Jan
authors.initials: J
authors.lastname: Clarke
authors.forename: Giselle
authors.initials: G
authors.lastname: Singer
authors.forename: Mark
authors.initials: M
authors.lastname: Lebwohl
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D005143:Eyelids / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009824:Ointments; D012720:Severity of Illness Index; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D009824:Ointments; D016559:Tacrolimus